You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Portal vein tumor thrombus,PVTT

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 4, 2023

Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus Trial (I-125 Seeds Brachytherapy in PVTT,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • I-125 Seeds Brachytherapy in PVTT
  • +2 more
  • (no location specified)
Aug 14, 2023

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone

Completed
  • Hepatocellular Carcinoma
  • TACE-HAIC
  • +3 more
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 8, 2022

Advanced Hepatocellular Carcinoma Trial in Guangzhou (drug, procedure, radiation)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Sun Yat-sen University
Oct 20, 2022

Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma Trial in Shanghai (radiation, combination product, drug)

Not yet recruiting
  • Liver Cancer
  • +4 more
  • intensity-modulated radiotherapy
  • +5 more
  • Shanghai, China
    Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
Apr 20, 2022

Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) Trial in Beijing (GSMs-TACE, Surgical Resection)

Unknown status
  • Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT)
  • GSMs-TACE
  • Surgical Resection
  • Beijing, China
    Beijing Changgung Hospital
Nov 26, 2020

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Trial in Shanghai (Tislelizumab, IMRT)

Not yet recruiting
  • Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
  • Shanghai, China
    Zhongshan hospital, Fudan University
Apr 19, 2021

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (TACE combined with sorafenib/lenvatinib and iodion-125 seeds

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • TACE combined with sorafenib/lenvatinib and iodion-125 seeds brachytherapy
  • TACE combined with sorafenib/lenvatinib
  • Guangzhou, Guangdong, China
    the Second Affiliated Hospital of Guangzhou Medical University
Jul 27, 2021

Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors Trial in Nanning (Cadonilimab,

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • +2 more
  • Nanning, Guangxi, China
    First Affiliated Hospital of Guangxi Medical University
Sep 13, 2023

Carcinoma, Hepatocellular, Liver Tumors, Sintilimab Trial in Guangzhou (Hepatic arterial infusion chemo, Lenvatinib, Sintilimab)

Unknown status
  • Carcinoma, Hepatocellular
  • +3 more
  • Hepatic arterial infusion chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Second Affiliated Hospital of Guangzhou Medical University
Dec 20, 2020

Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus Trial in Guangzhou (TACE combined with iodine-125 seeds

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • TACE combined with iodine-125 seeds implantation
  • TACE
  • Guangzhou, Guangdong, China
    The 2nd Affiliated Hospital of Guangzhou Medical University
Mar 2, 2022

Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Guangzhou (neo-TACE-HAIC+Surgery, Surgery alone)

Recruiting
  • Hepatocellular Carcinoma
  • Portal Vein Thrombosis
  • neo-TACE-HAIC+Surgery
  • Surgery alone
  • Guangzhou, Guangdong, China
  • +1 more
Oct 22, 2020

HCC With Portal Vein Tumor Thrombosis on Basis of Risk Scoring

Completed
  • Hepatocellular Carcinoma
  • +2 more
    • Daegu, DalSeo-gu, Korea, Republic of
      Keimyung university Dongsan Medical Center
    Aug 16, 2023

    Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Lenvatinib 1, Camrelizumab 1)

    Recruiting
    • Hepatocellular Carcinoma
    • Portal Vein Thrombosis
    • HAIC
    • +4 more
    • Beijing, Beijing, China
      Peking Univerisity Cancer Hospital
    Jan 10, 2022

    Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis Trial in Hangzhou (SBRT+TACE+Sorafenib, Sorafenib)

    Recruiting
    • Unresectable Hepatocellular Carcinoma
    • Portal Vein Thrombosis
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of Medicine, Zhejiang Uni
    Jun 15, 2020

    Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis Trial in Canada (Neoadjuvant)

    Recruiting
    • Hepatocellular Carcinoma
    • Portal Vein Tumour Thrombosis
    • Neoadjuvant
    • Calgary, Alberta, Canada
    • +6 more
    Oct 18, 2022

    Pancreatic Cancer, Pancreatic Adenocarcinoma Trial in Milan (EUS-guided Portal Vein sampling)

    Recruiting
    • Pancreatic Cancer
    • Pancreatic Adenocarcinoma
    • EUS-guided Portal Vein sampling
    • Milan, Italy
      IRCCS San Raffaele Scientific Institute
    Jun 2, 2022

    HepatoCellular Carcinoma, Portal Vein Thrombosis Trial in Beijing (HAIC, Sorafenib)

    Completed
    • HepatoCellular Carcinoma
    • Portal Vein Thrombosis
    • Beijing, Beijing, China
      Peking University Cancer Hospital
    Oct 8, 2021

    Radiotherapy, Toripalimab, Sorafenib Trial in Beijing (Radiotherapy plus Toripalimab, Sorafenib)

    Recruiting
    • Radiotherapy
    • +3 more
    • Beijing, Beijing, China
      Bo Chen
    Mar 6, 2021

    Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombosis, Stereotactic Body Radiotherapy Trial in Hangzhou

    Completed
    • Hepatocellular Carcinoma Non-resectable
    • +2 more
    • stereotactic body raiotherapy
    • Hangzhou, Zhejiang, China
      the second affiliated hospital of Zhejiang University
    Jul 11, 2021

    Hepatocellular Carcinoma Trial in Guangzhou (Hepatic artery infusion chemo(HAIC), Durvalumab)

    Recruiting
    • Hepatocellular Carcinoma
    • Hepatic artery infusion chemotherapy（HAIC）
    • Durvalumab
    • Guangzhou, Guangdong, China
      Department of Minimally Invasive and Interventional Radiology, L
    May 18, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (Toripalimab, Stereotactic body radiotherapy)

    Unknown status
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Nov 17, 2019

    Hepatocellular Carcinoma Trial in Hangzhou (Sintilimab Injection, TACE, Radiotherapy)

    Terminated
    • Hepatocellular Carcinoma
    • Sintilimab Injection
    • +2 more
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, School of Medicine, Zhejiang Univ
    Dec 21, 2021